Immunopharmacodynamic response to blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL).
Andrea Schub
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Research Funding - Amgen Research Munich GmbH
Virginie Nägele
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Gerhard Zugmaier
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Christian Brandl
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Youssef Hijazi
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Max S. Topp
Consultant or Advisory Role - Amgen
Other Remuneration - Amgen
Peter Kufer
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Andreas Wolf
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Matthias Klinger
Employment or Leadership Position - Amgen
Stock Ownership - Amgen